Intensive care unit (ICU) costs have doubled since 2000, totalling 108 billion dollars per year. Acute respiratory distress syndrome (ARDS) has a prevalence of 10.4% and a 28-day mortality of 34.8%. Noninvasive ventilation (NIV) is used in up to 30% of cases. A recent randomized controlled trial by Patel et al. (2016) showed lower intubation rates and 90-day mortality when comparing helmet to face mask NIV in ARDS. e population in the Patel et al. trial was used for cost analysis in this study. Projections of cost savings showed a decrease in ICU costs by $2527 and hospital costs by $3103 per patient, along with a 43.3% absolute reduction in intubation rates. Sensitivity analysis showed consistent cost reductions. Projected annual cost savings, assuming the current prevalence of ARDS, were $237538 in ICU costs and $291682 in hospital costs. At a national level, using yearly incidence of ARDS cases in American ICUs, this represents $449 million in savings. Helmet NIV, compared to face mask NIV, in nonintubated patients with ARDS, reduces ICU and hospital direct-variable costs along with intubation rates, LOS, and mortality. A large-scale cost-e ectiveness analysis is needed to validate the ndings.
Introduction
Our population is aging, hospital admissions are getting more frequent with a longer length of stay (LOS), intensive care and hospital occupancy rates are climbing, and healthcare-associated expenditures are increasing [1, 2] . Intensive care costs alone totalled 108 billion US dollars in 2010, nearly double that of 2000 (56 billion US dollars). ICU costs account for 13.2% of hospital expenditures and 0.72% of the gross domestic product in the United States, a 32% percent rise from 2000 to 2010 [1, 2] . It is estimated that a single day in the intensive care unit (ICU) costs 2500-4300 US dollars per patient, representing a 61.1% increase in costs over the same time period with the use of new medications, technologies, and specialized care [1] [2] [3] [4] . Moving forward, nding ways to reduce ICU costs will reduce the nancial burden of increasing utilization of ICU care. New practices focusing on cost-e ectiveness will be key by evaluating the e ectiveness of the practice on patient outcomes as well as the resources required to implement it [5] .
Acute respiratory distress syndrome (ARDS) has a worldwide prevalence of 10.4% in ICUs and an overall 28-day mortality of 34.8% [6] . In the absence of a proven mortality bene t, noninvasive ventilation (NIV) is used in up to 30% of patients with ARDS [6] [7] [8] . In June 2016, Patel et al. published the rst randomized controlled trial comparing helmet and face mask NIV for patients with ARDS [7] . e patients who received helmet NIV had a reduction in intubation rates, ICU LOS, and 90-day mortality, as well as increased ventilator-free days. Intubation rates were 61.5% in the face mask group, as opposed to 18.2% in the helmet group, giving an absolute risk reduction of 43.3% (95% CI 24.3-62.4%, p < 0.001). In fact, the trial was stopped early for e cacy at the rst interim analysis after one-third of planned patient enrollment.
Increased ventilator days are associated with longer LOS, higher risk of complications of intubation in ARDS such as pneumonia [9] , delirium [10] , and ICU-acquired weakness [11] , and a higher risk of mortality. Reducing intubation rates is therefore expected to reduce the number of complications and have signi cant cost savings.
Helmet NIV has been shown to provide similar oxygenation when compared to face mask NIV while providing better patient tolerability, less air leaks, and a universal size independent of facial anatomy [12, 13] .
is study was conducted to quantify the potential ICU and hospital cost savings of helmet NIV compared to face mask NIV in ARDS.
Methods
e population used to calculate ICU and hospital costs consists of patients with ARDS, treated with face mask or helmet NIV, studied in the randomized controlled trial by Patel et al. [7] . e total and individual patient costs of both study groups were calculated based on their reported ICU and hospital LOS. A cost analysis model proposed by Lord et al. [14] based on cost values published by Kahn et al. [15] was used to estimate average daily cost, which was then multiplied by the LOS values. is model calculates daily direct-variable costs in the ICU and on hospital wards. It assumes that ICU days are more expensive than ward days, that all ward days have the same cost, that the rst ICU day is the most expensive, and that the ICU cost decreases daily until day 5. All costs were in ated to 2016 US dollars using the overall consumer price index reported by the Bureau of Labor Statistics [16] . We calculated the di erence in costs by subtracting the costs of the helmet NIV group from the face mask NIV group. 95% con dence intervals were estimated using bootstrap resampling procedures with 1000 iterations. Potential cost savings were projected by assuming a 10% prevalence of ARDS, 30% use of NIV in ARDS, and identical cost of purchase of helmet and face mask NIV to then multiply average cost savings per patient with the potential number of ARDS patients per year treated with NIV.
Results
For the purpose of this paper, the population examined by Patel et al. was used as the study sample (as detailed in [7] ). e total number of patients is 83, 39 of which were treated with face mask NIV, and 44 with helmet NIV. Both groups were comparable in terms of age, severity of illness, medical history, reason for acute respiratory failure, PaO 2 : FiO 2 ratio, and the amount of respiratory support on NIV. Outcomes are presented in Table 1 . ere was a statistically signi cant reduction in endotracheal intubation (−43.3%, p < 0.001) and increase in ventilator-free days (8.4, p < 0.001) with helmet NIV. ere was also a reduction in ICU LOS, hospital LOS, and 90-day mortality with helmet NIV.
Absolute di erences in cost are shown in Table 2 . With a signi cant reduction in ICU and hospital LOS in the helmet NIV group, associated ICU and hospital costs were reduced by 2527 US dollars and 3103 US dollars per patient, respectively. e total cost saving in the care of the helmet NIV group was 71842 US dollars.
A sensitivity analysis was conducted to assess potential variations in ICU and hospital costs, according to varying ICU lengths of stay, for either the face mask or the helmet group, or both. As shown in Table 3 , even by increasing the helmet group's ICU LOS, helmet NIV consistently represented a cost-saving method to treat patients with ARDS. For example, a one-day increase in ICU LOS for the helmet group and a steady ICU LOS for the face mask group lead to a reduction in ICU and hospital costs of 1712 US dollars and 2288 US dollars per patient, respectively, favoring helmet NIV. To note, these analyses manipulated LOS regardless of outcome, which was expected to remain stable across groups throughout the sensitivity analysis. However, as helmet NIV group patients are expected to show a greater proportion of successful outcomes, the sensitivity analysis may be seen as conservative in the magnitude of the advantage it indicates for helmet use.
Discussion
is cost analysis shows a consistent reduction in cost associated with the use of helmet NIV in the ARDS population studied by Patel et al. [7] along with a reduction in intubation rates, LOS, and mortality. Potential savings could be illustrated despite variations in LOS with the sensitivity analysis, and these savings were extrapolated to di ering volumes of ARDS. is analysis represents an important step in nding a cost-e cient, well-tolerated, and easily applicable way to deliver care to patients with ARDS who are not intubated at the time of assessment and admission to the ICU. As mentioned, this represents up to 30% of patients with ARDS. Importantly, single interventions with a mortality bene t in the care of ICU patients such as this one are uncommon [17] . e magnitude of potential savings at a national level is immense. 5.7 million patients are admitted to an ICU each year in the United States [18] , and 10.4% of them are assumed to have ARDS [6] . is corresponds to 592800 patients who are admitted with ARDS yearly. Assuming that up to 30% of these patients are treated with NIV, which is to say 177840 patients, the use of the helmet interface would lead to potential total savings of 449 million US dollars when compared to the face mask interface.
Limitations to this cost analysis lie in the assumptions of the model. Firstly, calculations were based on a randomized and controlled, but single-center, unblended, and small study population. is center was also accustomed to using the helmet NIV interface. In order to avoid unwarranted variability, centers unaccustomed to the use of helmet NIV would need to be included in future studies, to avoid selection bias based on established experience with the interface. Secondly, costs were obtained from a model developed from a separate single-center's nancial data. In order to establish that helmet NIV is a truly cost-e ective way of treating nonintubated patients with ARDS, a large multicenter health economic evaluation, comparing costs and outcomes of the helmet to the face mask NIV, interfaces would need to be done. Hospitals would track direct costs concurrently and include the cost of the apparatus of NIV (face masks, helmets, etc.) in the analyses, in order to provide exact rather than projected costs. It would not be possible to perform a blinded study as patients and healthcare providers would evidently notice with which group of NIV delivery they were interacting. However, the bias of not being blinded is unlikely to a ect results due to the presence of objective indications for intubation and progression of respiratory illness. Also this study's costing methods do not incorporate major cost drivers such as extracorporeal membrane oxygenation (ECMO) or renal replacement therapy, which may be seen in severe cases of ARDS.
It is noteworthy that the majority of costs in the ICU are xed. An intervention such as the use of helmet NIV in ARDS has the potential to decrease direct-variable ICU 
Conclusion
e use of the helmet NIV interface, when compared to the face mask interface in the management of nonintubated patients with ARDS, reduces intubation rates and mortality, as well as ICU and hospital costs. e savings from such an intervention are potentially immense from a national standpoint, and they represent an opportunity to redistribute direct-variable ICU funds to other evidence-based bene cial therapies, such as early mobility initiatives.
Future studies could conduct a cost-e ectiveness analysis comparing cost and health outcomes associated with each NIV interface. Cost-e ectiveness analyses are crucial to minimize preventable expenses and ensure sustainability in the health sector, an ever-growing need in today's climate.
ese analyses could be incorporated in large-scale trials looking at new interventions and clinical guideline development by focusing on cost e ectiveness. ey could also be integrated in the comparison of two or more therapies with already established bene ts for the same disease or syndrome. A relevant example is that of the comparison of outcomes and costs associated with the use of helmet NIV and high-ow nasal oxygen in acute hypoxic respiratory failure. ose potential studies would enrich this domain of research even further and contribute to build a more sustainable healthcare system for aging populations.
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